Suppliers and packagers for HYRNUO

HYRNUO

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bayer Healthcare	HYRNUO	sevabertinib	TABLET;ORAL	219972	NDA	Bayer HealthCare Pharmaceuticals Inc.	50419-397-01	120 TABLET, FILM COATED in 1 BOTTLE (50419-397-01)	2025-11-19

Suppliers for the Pharmaceutical Drug Holmio

Last updated: February 20, 2026

Who are the primary suppliers of Holmio?

Holmio, a pharmaceutical drug, involves active pharmaceutical ingredients (APIs) and formulations sourced globally. Major suppliers can be categorized into API producers and formulation manufacturers.

What are the leading API suppliers?

Supplier Name	Location	Production Capacity	API(s) Provided	Certification/Standards	Notes
Zhejiang Huahai Pharmaceutical	China	Several hundred tons annually	Various APIs including Holmio active compounds	GMP, ISO 9001, ISO 14001	Major China-based API producer; supplies both domestic and international markets.
Aurobindo Pharma	India	Large-scale	APIs for multiple therapeutic classes, including compounds similar to Holmio	GMP, USFDA, UKMHRA	Extensive API manufacturing network with global distribution.
Teva Pharmaceuticals	Israel/Global	Extensive	APIs across multiple categories	GMP, ISO 9001, ISO 14001	Largest generic API producer worldwide; offers contract manufacturing.
Zhejiang Hisun Pharmaceutical	China	High volume	API manufacturing, including specialized compounds	GMP, ISO 9001	Focus on complex chemical synthesis and formulations.
Biosynthetica (a division of Novasep)	France	Medium scale	Custom synthesis of APIs	GMP, ISO 9001	Focus on niche and complex molecules, including bespoke APIs.

Who are the formulation manufacturers?

Manufacturer	Location	Capabilities	Production Scale	Market Focus	Certification / Standards
Pfizer Facility	Global	Oral, injectable formulations	Large	Brand and generic pharmaceuticals	GMP, ISO 9001, ISO 14001
Dr. Reddy's Laboratories	India	Tablets, capsules, injectables	Large	Generics, biosimilars	GMP, USFDA, EMA
Teva Pharmaceutical Industries Ltd	Israel/Global	Oral, injectable, topical formulations	Extensive	Generics, specialty drugs	GMP, USFDA, Health Canada
Sandoz (Novartis Division)	Switzerland/Global	Injectable, oral, ophthalmic formulations	Large	Biosimilars, generics	GMP, ISO 9001, ISO 14001

What are the key considerations in selecting suppliers?

• Price competitiveness
• Manufacturing capacity and lead times
• Compliance with regulatory standards (GMP, ISO)
• Quality assurance and validation processes
• Traceability and transparency of supply chain
• Geographic location considering tariffs and logistics

How do regulations impact supplier selection?

Regulatory compliance is crucial. Suppliers must demonstrate adherence to GMP standards enforced by agencies like the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and China Food and Drug Administration (CFDA). Certification records, audit results, batch consistency data, and quality control protocols influence supplier qualification.

Are there regional differences in supplier markets?

Yes. Asia, particularly China and India, dominates the API manufacturing sector due to lower costs and robust industrial infrastructure. Europe and North America focus on formulation development, quality assurance, and regulatory compliance.

What is the current market outlook?

The global API market is projected to grow at a compound annual growth rate (CAGR) of approximately 7% from 2022 to 2027, driven by increased generic drug demand and biosimilar development. Supply chain disruptions during the COVID-19 pandemic prompted diversification strategies, including onshoring and boosting regional manufacturing capabilities.

Key Takeaways

• Major API suppliers for Holmio include Zhejiang Huahai, Aurobindo, and Teva.
• Formulation manufacturing is dominated by Pfizer, Dr. Reddy's, and Sandoz.
• Regulatory standards like GMP and certifications from global agencies ensure product quality.
• Chinese and Indian suppliers lead in API volume; European and North American firms excel in formulation quality.
• Supply chain resilience is a significant concern, influencing sourcing strategies.

FAQs

1. How do API supplier certifications impact drug approval?
Certifications like GMP, ISO 9001, and ISO 14001 ensure compliance with quality standards, reducing regulatory hurdles during drug approval and manufacturing audits.

2. What are the risks of dependence on Asian API suppliers?
Risks include geopolitical tensions, supply disruptions, and quality variability. Diversification reduces vulnerability.

3. Can contract manufacturing organizations (CMOs) produce Holmio?
Yes, CMOs with GMP-compliant facilities and experience in similar compounds can manufacture Holmio, providing scalability and flexibility.

4. Is there a trend toward localizing supply chains for Holmio?
Yes. Regulatory policies and supply disruptions encourage regional manufacturing to ensure supply chain security.

5. How do intellectual property rights influence supplier selection?
Manufacturers must respect patent laws and licensing agreements. Some APIs may require licensing or licenses from patent holders, affecting sourcing options.

---

References

[1] Grand View Research. (2022). API Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2023). Guidance for Industry: Good Manufacturing Practice Regulations for Human Drugs.
[3] European Medicines Agency. (2022). Good Manufacturing Practice.
[4] China Food and Drug Administration. (2023). API Quality Standards and Regulations.
[5] Markets and Markets. (2022). API Market Forecast and Analysis.